GSK3B and Myotonia: Since activity of CUGBP1 is controlled by GSK3β, correction of GSK3β in CDM1 or DM1 models restores CUGBP1 activity and improves muscle (myotonia, weakness, atrophy, myopathy) and CNS (anxiety) phenotypes.